Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BMS-986416 / BMS, Ono Pharma
NCT03834662: A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies From AVID200-03 trial in solid tumor at SITC 2019 Nov 2019 - Nov 2019: From AVID200-03 trial in solid tumor at SITC 2019 From AVID200-03 trial in solid tumor at SITC 2019 Nov 2019 - Nov 2019: From AVID200-03 trial in solid tumor at SITC 2019 Completion of enrollment of P1a trial in solid tumor Oct 2019 - Oct 2019: Completion of enrollment of P1a trial in solid tumor More	Completed	1	19	Canada, US	AVID200, TGFβ receptor ectodomain-IgG Fc fusion protein	Bristol-Myers Squibb, Formation Biologics	Malignant Solid Tumor	02/20	02/20
NCT03831438: Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis	Completed	1	9	US	AVID200, AVID200 DP	Bristol-Myers Squibb	Scleroderma, Diffuse	06/20	06/20
NCT04943900: A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors	Completed	1	67	Europe, Canada, Japan, US, RoW	BMS-986416, Nivolumab, BMS-936558, Opdivo	Bristol-Myers Squibb	Advanced Solid Tumors	02/25	02/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BMS-986416 / BMS, Ono Pharma
NCT03834662: A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies From AVID200-03 trial in solid tumor at SITC 2019 Nov 2019 - Nov 2019: From AVID200-03 trial in solid tumor at SITC 2019 From AVID200-03 trial in solid tumor at SITC 2019 Nov 2019 - Nov 2019: From AVID200-03 trial in solid tumor at SITC 2019 Completion of enrollment of P1a trial in solid tumor Oct 2019 - Oct 2019: Completion of enrollment of P1a trial in solid tumor More	Completed	1	19	Canada, US	AVID200, TGFβ receptor ectodomain-IgG Fc fusion protein	Bristol-Myers Squibb, Formation Biologics	Malignant Solid Tumor	02/20	02/20
NCT03831438: Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis	Completed	1	9	US	AVID200, AVID200 DP	Bristol-Myers Squibb	Scleroderma, Diffuse	06/20	06/20
NCT04943900: A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors	Completed	1	67	Europe, Canada, Japan, US, RoW	BMS-986416, Nivolumab, BMS-936558, Opdivo	Bristol-Myers Squibb	Advanced Solid Tumors	02/25	02/25